UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials

Clinical infectious diseases, 2020-09, Vol.71 (6), p.1379-1389

2020

Volltextzugriff (PDF)

Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco

PloS one, 2010-06, Vol.5 (6), p.e11068-e11068

2010

Volltextzugriff (PDF)

Lack of an association between clinical INSTI-related body weight gain and direct interference with MC4 receptor (MC4R), a key central regulator of body weight

PloS one, 2020-02, Vol.15 (2), p.e0229617-e0229617

2020

Volltextzugriff (PDF)

Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected Adults

Journal of acquired immune deficiency syndromes (1999), 2016-11, Vol.73 (3), p.294-298

2016

Volltextzugriff (PDF)

A Randomized, Open-Label Trial to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Darunavir in Treatment-Experienced HIV-1-Infected Adults

Journal of acquired immune deficiency syndromes (1999), 2017-02, Vol.74 (2), p.193-200

2017

Volltextzugriff (PDF)

Proactive strategies to optimize engagement of Black, Hispanic/Latinx, transgender, and nonbinary individuals in a trial of a novel agent for HIV pre-exposure prophylaxis (PrEP)

PloS one, 2022-06, Vol.17 (6), p.e0267780-e0267780

2022

Volltextzugriff (PDF)

Plasma concentration of neurofilament light chain protein decreases after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate

PloS one, 2019-12, Vol.14 (12), p.e0226276

2019

Volltextzugriff (PDF)

Ending the HIV Epidemic for Persons Left Behind in the Advances of HIV: Intervention Studies Addressing the HIV Continuum of Care

Research on social work practice, 2023-02, Vol.33 (2), p.230-241

2023

Volltextzugriff (PDF)

Atherosclerotic Cardiovascular Disease Risk Profile of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate

Open forum infectious diseases, 2020-01, Vol.7 (1), p.ofz472

2020

Volltextzugriff (PDF)

HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens

PloS one, 2020-01, Vol.15 (1), p.e0224875-e0224875

2020

Volltextzugriff (PDF)

Aripiprazole for the treatment of methamphetamine dependence: a randomized, double-blind, placebo-controlled trial

Addiction (Abingdon, England), 2013-04, Vol.108 (4), p.751-761

2013

Volltextzugriff (PDF)

Not all missed doses are the same: sustained NNRTI treatment interruptions predict HIV rebound at low-to-moderate adherence levels

PloS one, 2008-07, Vol.3 (7), p.e2783-e2783

2008

Volltextzugriff (PDF)

Efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in Asian participants with human immunodeficiency virus 1 infection: A sub-analysis of phase 3 clinical trials

HIV research & clinical practice, 2019-05, Vol.20 (3), p.73-81

2019

Volltextzugriff (PDF)

Beyond Measuring What Matters to Managing What Matters: Improving Public Health Quality and Accountability in the U.S. HIV Epidemic Response

Public health reports (1974), 2013-09, Vol.128 (5), p.360-363

Das, Moupali

2013

Volltextzugriff (PDF)

Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide

EBioMedicine, 2016-11, Vol.13 (C), p.321-327

2016

Volltextzugriff (PDF)

Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis

Annals of internal medicine, 2020-09, Vol.173 (6), p.506-507

2020

Volltextzugriff (PDF)

Using Twitter to Survey Alcohol Use in the San Francisco Bay Area

Epidemiology (Cambridge, Mass.), 2015-07, Vol.26 (4), p.e39-e40

2015

Volltextzugriff (PDF)

Bringing the end in sight: consensus regarding HIV screening strategies

Annals of internal medicine, 2013-07, Vol.159 (1), p.63

2013

Volltextzugriff (PDF)

Pharmacokinetics of Tenofovir Alafenamide When Coadministered With Other HIV Antiretrovirals

Journal of acquired immune deficiency syndromes (1999), 2018-08, Vol.78 (4), p.465-472

2018

Volltextzugriff (PDF)

Weight Change Following Antiretroviral Therapy Switch in People With Viral Suppression: Pooled Data from Randomized Clinical Trials

Clinical infectious diseases, 2021-10, Vol.73 (8), p.1440-1451

2021

Volltextzugriff (PDF)

Linkage and Retention in HIV Care among Men Who Have Sex with Men in the United States

Clinical infectious diseases, 2011-01, Vol.52 (suppl_2), p.S214-S222

2011

Volltextzugriff (PDF)

Two-dose emtricitabine/tenofovir alafenamide plus bictegravir prophylaxis protects macaques against SHIV infection

Journal of antimicrobial chemotherapy, 2021-02, Vol.76 (3), p.692-698

2021

Volltextzugriff (PDF)

Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials

AIDS (London), 2019-07, Vol.33 (9), p.1455-1465

2019

Volltextzugriff (PDF)

Compassionate Use of Remdesivir in Children With Severe COVID-19

Pediatrics (Evanston), 2021-05, Vol.147 (5), p.1

2021

Volltextzugriff (PDF)

1 – 25 von 115

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(106)
Mit Volltextzugriff
(92)

Publikationsform

Artikel
(112)
Buchkapitel
(3)

Sprache

Englisch
(115)
Japanisch
(6)

Erscheinungsjahr

n.n

Thema

Science & Technology
(65)
Life Sciences & Biomedicine
(58)
Humans
(54)
Hiv
(49)
Human Immunodeficiency Virus
(42)
Infectious Diseases
(40)
Male
(39)
Female
(26)
Adult
(25)
Hiv Infections - Drug Therapy
(25)
Immunology
(25)
Middle Aged
(20)
Public Health
(19)
Acquired Immune Deficiency Syndrome
(18)
Aids
(18)
Hiv Infections - Prevention & Control
(18)
Hiv Infections - Epidemiology
(17)
Antiretroviral Drugs
(16)
Aids/hiv
(15)
Disease Prevention
(15)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials

Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco

Lack of an association between clinical INSTI-related body weight gain and direct interference with MC4 receptor (MC4R), a key central regulator of body weight

Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected Adults

A Randomized, Open-Label Trial to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Darunavir in Treatment-Experienced HIV-1-Infected Adults

Proactive strategies to optimize engagement of Black, Hispanic/Latinx, transgender, and nonbinary individuals in a trial of a novel agent for HIV pre-exposure prophylaxis (PrEP)

Plasma concentration of neurofilament light chain protein decreases after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate

Ending the HIV Epidemic for Persons Left Behind in the Advances of HIV: Intervention Studies Addressing the HIV Continuum of Care

Atherosclerotic Cardiovascular Disease Risk Profile of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate

HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens

Aripiprazole for the treatment of methamphetamine dependence: a randomized, double-blind, placebo-controlled trial

Not all missed doses are the same: sustained NNRTI treatment interruptions predict HIV rebound at low-to-moderate adherence levels

Efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in Asian participants with human immunodeficiency virus 1 infection: A sub-analysis of phase 3 clinical trials

Beyond Measuring What Matters to Managing What Matters: Improving Public Health Quality and Accountability in the U.S. HIV Epidemic Response

Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide

Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis

Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial

Using Twitter to Survey Alcohol Use in the San Francisco Bay Area

Bringing the end in sight: consensus regarding HIV screening strategies

Pharmacokinetics of Tenofovir Alafenamide When Coadministered With Other HIV Antiretrovirals

Weight Change Following Antiretroviral Therapy Switch in People With Viral Suppression: Pooled Data from Randomized Clinical Trials

Linkage and Retention in HIV Care among Men Who Have Sex with Men in the United States

Two-dose emtricitabine/tenofovir alafenamide plus bictegravir prophylaxis protects macaques against SHIV infection

Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials

Compassionate Use of Remdesivir in Children With Severe COVID-19

Suchergebnisse filtern